A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy

Inclusion Criteria: * Males and females of all races and ethnicities between the ages of 50-99 * Female subjects must be 1-year postmenopausal or surgically sterilized and must have negative serum pregnancy test * Subjects must have GA from AMD in one or both eyes: * The study eye will be the eye that meets all inclusion/exclusion criteria * If both eyes meet criteria, then the eye with the smaller GA lesion will be studied * If the GA lesions are equal in size, then the eye with the best-corrected visual acuity (BCVA) will chosen as the study eye * If both eyes have the same lesion size and same BCVA, the right eye will be chosen * Subjects must have the following GA criteria for inclusion: * GA lesions with an area \> 2.5mm2 and ≤ 20mm2 as determine by fluorescein angiography and fundus autofluorescence * A clear view to the fundus must be present in order to easily examine the study eye at baseline * BCVA In the study eye between 20/20 and 20/100 as measured on Snellen chart or 85-50 letters by ETDRS * Willing and able to provide signed informed consent prior to any study participation Exclusion Criteria: * GA due to a disease other than AMD * Pregnancy or lactation * Treatment of any systemic infection * Autofluorescence pattern marked at none, focal or patchy * Ocular surgery in the study eye in the previous 6 months. * Presence or history of choroidal neovascularization (wet AMD) in the study eye * Any inflammatory (autoimmune, uveitis) or neovascular (diabetic retinopathy) disease of the retina * Any history of glaucoma or disc cupping in the study eye * Any history of severe dry eye disease * High myopia \> - 8D or high hyperopia \> +8D in the study eye * Presence of life-threatening disease * Abnormal basal metabolic panel or liver function tests * Current alcohol or other substance abuse * Unwilling or unable to provide signed informed consent for any study procedures